课题基金 / 基金详情

PHASE III MULTINATIONAL DOUBLE-BLIND STUDY OF RECOMBINANT HUMAN ANTI-P185HER2

PHASE III MULTINATIONAL DOUBLE-BLIND STUDY OF RECOMBINANT HUMAN ANTI-P185HER2
重组人抗 P185HER2 的 III 期多国双盲研究
批准号：
6245652
负责人：
BARRY LEMBERSKY
金额：
$1.76万
依托单位：
UNIVERSITY OF PITTSBURGH AT PITTSBURGH
依托单位国家：
美国
项目类别：
财政年份：
1997
资助国家：
美国
项目状态：
已结题
起止时间：
1997-03-18 至 1997-11-30
来源：
https://reporter.nih.gov/project-details/6245652
关键词：
breast neoplasms clinical research combination cancer therapy cyclophosphamide doxorubicin female human subject human therapy evaluation metastasis monoclonal antibody neoplasm /cancer chemotherapy neoplasm /cancer immunotherapy recombinant proteins

项目摘要

项目成果

BARRY LEMBERSKY的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
This is a Phase III randomized, placebo-controlled, double-blind, multinational study comparing recombinant antibody (rhuMAbHER2) + cyclophosphamide & doxorubicin with placebo + cyclophosphamide & doxorubicin. Approximately 450 patients with HER2/neu overexpression who have not received prior cytotoxic chemotherapy for metastatic breast cancer will be enrolled in the study. Patients will be equally randomized to one of two treatment groups. Patients will be monitored over time to evaluate the efficiency & safety of rhuMAbHER2.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
RECOMBINANT HUMANIZED ANTI-185HER2 MONOCLONAL ANTIBODY IN BREAST CANCER
PHASE III MULTINATIONAL STUDY OF IV RECOMBINANT HUMANIZED ANTIP185HER2 MAB
PHASE III MULTINATIONAL DOUBLE-BLIND STUDY OF RECOMBINANT HUMAN ANTI-P185HER2
  • 批准号：
    5218443
  • 项目类别：
  • 资助金额：
    $0.0万
  • 财政年份：
    --
  • 负责人：
    BARRY LEMBERSKY
  • 依托单位：
    --
海外基金